英文药名：Mirapex(pramipexole tablets)

中文药名：米拉帕(普拉克索片)

生产厂家：Kohlpharm

给药说明
拉克索副作用;别名:米拉帕、Trivastal、Mirapex;普拉克索适应症:本品主要用于治疗帕金森病及其综合征。可单用或与左旋多巴合用。;普拉克索药理学作用:本品是人工合成的氨苯噻唑(aminobenzothiazole)的衍生物。具有D2-受体激动剂活性。采用UPDRS评分评估本品对早期帕金森病的作用，与安慰剂对照组相比，用药组患者生活能力显著改善，呈“关”状态的时间明显缩短，但两组患者的运动功能检查评分没有差别。

分类名称
 
一级分类：神经系统药物 二级分类：抗帕金森病药 三级分类：作用于多巴胺能受体的药物 
 
药品英文名
Pramipexole
 
药品别名
米拉帕、Trivastal  Mirapex
 
药物剂型
片剂：0.18μg，0.52μg，0.70μg，1.05μg，2.1μg，3.15μg。
 
药理作用
本品是人工合成的氨苯噻唑(aminobenzothiazole)的衍生物。具有D2-受体激动剂活性。采用UPDRS评分评估本品对早期帕金森病的作用，与安慰剂对照组相比，用药组患者生活能力显著改善，呈“关”状态的时间明显缩短，但两组患者的运动功能检查评分没有差别。
 
药动学
空腹口服后可迅速吸收，2h可达血药峰值；进食时口服本品后，3h达血药峰值。消除t1/2约9h，生物利用度＞90%，只有小部分被代谢，几乎全部经肾排出。
 
适应证
本品主要用于治疗帕金森病及其综合征。可单用或与左旋多巴合用。
 
禁忌证
哺乳者禁用。
 
注意事项
1.肾功能不全者慎用。
2.可引起睡眠发作，因此开车和机械操作者应特别注意。
 
不良反应
有幻觉、嗜睡、运动障碍、口干、恶心、便秘等. 
 
用法用量
在开始第1周中，口服125μg，每天3次，第2周，口服250μg，每天3次；以后每周增加750μg，达最高每天4.5mg。
 
药物相应作用
西咪替丁可减少本品的清除。
 
专家点评
本品为一种选择性作用于多巴胺D3受体的多巴胺激动剂。可明显减少帕金森病静息时的震颤。晚期帕金森病用该药与左旋多巴共同治疗时，可使患者对左旋多巴需要量减少，并可延长症状最佳控制时间平均每天2h。有报道表明，虽然本品可用于治疗帕金森氏病及其综合征，但临床效果不肯定。
 Indication:
MIRAPEX ER tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD).

Important Safety Information:
MIRAPEX ER may cause patients to fall asleep without warning signs during activities of daily living, including driving, which sometimes resulted in accidents. Some events may occur well after the start of treatment. Advise patients that, until they know how MIRAPEX ER affects them, or if they experience increased somnolence or episodes of falling asleep, they should not engage in potentially dangerous activities.

There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone and that are generally used for the treatment of PD, including MIRAPEX ER. Consider dose reduction or stopping MIRAPEX ER if a patient develops such urges.

As patients may not recognize or acknowledge increased drowsiness, sleepiness, or behavioral changes, prescribers should continually reassess patients.

Symptomatic orthostatic hypotension may occur, especially during initial treatment or dose escalation.

Hallucinations may occur at any time during treatment. MIRAPEX ER may potentiate the dopaminergic side effects of levodopa and may cause and/or exacerbate dyskinesia.

In a clinical trial for early PD, the most commonly reported adverse events with MIRAPEX ER that were more frequent than with placebo are somnolence, nausea, constipation, dizziness, fatigue, hallucinations, dry mouth, muscle spasms, and peripheral edema. In a clinical trial for advanced PD, the most commonly reported adverse events with MIRAPEX ER that were more frequent than with placebo are dyskinesia, nausea, constipation, hallucinations, headache, and anorexia.

以下产品的包装规格与剂型是在德国本地销售规格（其它剂量没有，由不同厂家，可以指定）
100片*0.18mg
100片*0.52mg
100片*0.70mg
100片*1.05mg
100片*2.1mg
100片*3.15mg